Nagashima M, Watanabe T, Terasaki M, et al
Plaintiffs lawyers contend that Ozempic was promoted to lower blood sugar and help patients lose weight by helping them curb appetite, but the risks to the stomach were understated or omitted entirely
Real Results: A patient experienced heavy shedding at month 5 on GLP-1s and feared permanent baldness
Data is quite clear
Pharmaceutical companies should warn people about dangerous, unexpected side effects from their drugs, and many people believe that Novo Nordisk did not do enough to warn the public
Germany is expected to maintain its leadership position with a 26.8% market share in 2025, remaining stable at 26.6% by 2035, supported by its advanced healthcare technology sector, precision diabetes care capabilities, and comprehensive pharmaceutical innovation facilities serving European and international markets